Practical implications of differential discounting in cost-effectiveness analyses with varying numbers of cohorts

Value in Health

Volumn 14, Issue 4, 2011, Pages 438-442

  O'Mahony, James F ^a,b   De Kok, Inge M C M ^a   Van Rosmalen, Joost ^a   Habbema, J Dik F ^a   Brouwer, Werner ^c   Van Ballegooijen, Marjolein ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Cohort models; Cost effectiveness analysis; Differential discounting; Population models; Study comparability

Indexed keywords

ARTICLE; CANCER PREVENTION; CLINICAL PRACTICE; CLINICAL RESEARCH; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE PRACTICE; HUMAN; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCREENING; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

EID: 79960015638     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2010.09.009     Document Type: Article

References (35)

1. Drummond M, Sculpher M, Torrance G, et al. Methods for the Economic Evaluation of Health Care Programmes (3rd ed). Oxford: Oxford University Press, 2005.
2. Gravelle H, Smith D. Discounting for health effects in cost-benefit and cost-effectiveness analysis. Health Econ 2001;10:587-99. (Pubitemid 32998371)
3. Keeler EB, Cretin S. Discounting of life-saving and other nonmonetary effects. Manage Sci 1983;29:300-6.
4. Weinstein MC, Stason W. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977;296:716-21. (Pubitemid 8066534)
5. Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. Oxford: Oxford University Press, 1996.
6. van Hout B. Discounting costs and effects: a reconsideration. Health Econ 1998;7:581-94. (Pubitemid 28521897)
7. Brouwer WBF, Niessen LW, Postma MJ, et al. Need for differential discounting of costs and health effects in cost effectiveness analyses. Br Med J 2005;331:446-8. (Pubitemid 41176388)
8. Claxton K, Sculpher M, Culyer A, et al. Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion. Health Econ 2006;15:1-4. (Pubitemid 43141521)
9. Gravelle H, Brouwer W, Niessen L, et al. Discounting in economic evaluations: stepping forward towards optimal decision rules. Health Econ 2007;16:307-17. (Pubitemid 46431778)
10. Smith DH, Gravelle H. The practice of discounting in economic evaluations of healthcare interventions. Int J Technol Assess Health Care 2001;17:236-43. (Pubitemid 32574961)
11. Williams A. Welfare economics and health status management. In: van der Gaag J, Perlman M, eds., Health, Economics and Health Economics. Amsterdam: North Holland Publishing, 1981.
12. Klok RM, Brouwer WBF, Annemans LJP, et al. Towards a healthier discount procedure. Expert Rev Pharmacoecon Outcomes Res 2005;5:59-63. (Pubitemid 40590124)
13. Meerding WJ, Bonsel GJ, Brouwer WBF, et al. Social time preferences for health and money elicited with a choice experiment. Value Health 2010.
14. Claxton K, Paulden M, Gravelle H, et al. Discounting and decision making in the economic evaluation of health care technologies. Health Econ 2010;20:2-15. doi: 10.1002/hec.1612.
15. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Pharmacoeconomic guidelines around the world. Available from: http://www.ispor.org/PEguidelines/index.asp [Accessed January 8, 2009].
16. College voor Zorgverzekeringen. Richtlijnen voor farmaco-economisch onderzoek, geactualiseerde versie [in Dutch]. The Netherlands, 2006.
17. Federaal Kenniscentrum voor de Gezondheidszorg. Guidelines for pharmacoeconomic evaluations in Belgium. Brussels, 2008.
18. Severens J, Milne R. Discounting health outcomes in economic evaluation: the ongoing debate. Value Health 2004;7:397-401. (Pubitemid 39038448)
19. Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy 2004;9:110-8. (Pubitemid 38568540)
20. Buxton MJ, Drummond MF, van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997;6:217-27. (Pubitemid 27296586)
21. Kuntz KM, Weinstein MC. Modelling in economic evaluation. In: Drummond M, McGuire A, eds. Economic Evaluation in Health Care: Merging Theory with Practice. Oxford: Oxford University Press, 2001.
22. Hoyle M, Anderson R. Whose costs and benefits? Why economic evaluations should simulate both prevalent and all future incident patient cohorts. Med Decis Making 2010;30:426-37.
23. Dewilde S, Anderson R. The cost-effectiveness of screening programs using single and multiple birth cohort simulations: a comparison using a model of cervical cancer. Med Decis Making 2004;24:486-92. (Pubitemid 39223701)
24. Kim JJ, Brisson M, Edmunds WJ, et al. Modeling cervical cancer prevention in developed countries. Vaccine 2008;26:K76-K86.
25. Habbema JDF, Boer R, Barendregt J. Chronic disease modeling. In: Heggenhougen K, Quah S, eds. International Encyclopedia of Public Health. San Diego: Academic Press, 2008.
26. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004;13:437-52. (Pubitemid 38660393)
27. de Kok IMCM, van Ballegooijen M, Habbema JDF. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst 2009;101:1083-92.
28. Lipscomb J, Weinstein MC, Torrence GW. Time preference. In: Gold MR, Siegel JE, Russell LB, et al., eds. Cost-Effectiveness in Health and Medicine. Oxford: Oxford University Press, 1996.
29. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 2008;26:733-44.
30. Paulden M, Claxton K. Budget allocation and the revealed social rate of time preference for health. Health Econ 2011 Mar 24. [Epub ahead of print].
31. Beutels P, Van Doorslaer E, Van Damme P, et al. Methodological issues and new developments in the economic evaluation of vaccines. Expert Rev Vaccines 2003;2:649-60. (Pubitemid 37295363)
32. Cooper K, Brailsford S, Davies R, et al. A review of health care models for coronary heart disease interventions. Health Care Manag Sci 2006;9:311-24. (Pubitemid 44736856)
33. Cairns J. Discounting and health benefits: another perspective. Health Econ 1992;1:76-9.
34. Cohen BJ. Discounting in cost-utility analysis of healthcare interventions: reassessing current practice. Pharmacoeconomics 2003;21:75-87. (Pubitemid 36127004)
35. Parsonage M, Neuburger N. Discounting and health benefits. Health Econ 1992;1:71-6.